Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 14 2018

A Hassidic Mother’s Promise to Donate a Kidney: Mission Accomplished

A young girl named Esti had a best friend named Tali whose father had kidney disease. He passed away before a kidney transplant could save his life.

READ MORE ›
alt_text

Friday, Nov 9 2018

Children with Low Vision Receive Unique Care at Hadassah

“The vision of world-renowned Prof. Isaac Caesar Michaelson, former Director of the Hadassah Medical Organization’s Department of Ophthalmology, of creating in 1973 The Jerusalem Institute for the Prevention of Blindness still amazes me,” says Dr. Claudia Yahalom, current head of the renamed Michaelson Institute for Rehabilitation of Vision at Hadassah Hospital Ein Kerem.

READ MORE ›
alt_text

Tuesday, Nov 6 2018

Hadassah Staff Saves Seven-Year-Old From Deadly Scorpion Bite

The intensity of his cry alerted Elisha Alush’s parents that something serious had happened to their seven-year-old. He ran in from the backyard of their home near Jericho, north of Jerusalem, screaming, “My foot, my foot.” And then he lost consciousness.

READ MORE ›
alt_text

Thursday, Nov 1 2018

Hadassah Saves Soccer Fan’s Life in Newly Inaugurated Heart Center

Mickey Peretz, age 36, began his evening at a Beitar Jerusalem soccer game. Little did he know that he would end the evening being the first patient to receive a life-saving heart catheterization in Hadassah Hospital Ein Kerem’s brand new Irma and Paul Milstein Heart Center.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More